SOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary artificial intelligence platform, announces the presentation of the top-line results of a Phase IIb study with SOM3355 compound on Huntington’s disease patients with chorea at the Annual Meeting of the Huntington Study Group (HSG) in Cincinnati, Ohio, on 7-9 November 2024 at the session ‘Contemporary Trials and Next Steps’.
Silvia Panigone, PhD, MBA, recently appointed as SOM’s new chief executive officer, says: “We are excited to share the results of the Phase IIb study that tested two different doses of SOM3355 in patient with chorea associated with Huntington’s disease. It has been a long journey for the company and we are proud to have achieved this important milestone.”
“We believe that the future of the treatment of chorea associated with Huntington’s disease will be driven by the use of drugs that are most effective by combining improvement of chorea and no significant negative impact on depression, suicidal ideation and cognitive function, thus allowing long-term continued treatment without additional limitation of the daily living,” says Rossella Medori, MD, the new chief medical officer at SOM Biotech.
“At this year’s HSG congress, we will present data from a just completed Phase IIb clinical trials with SOM3355, our lead asset. This drug was identified by SOM’s AI platform and selected to be re-purposed in this indication thanks to a well-established safety profile and the new mechanism-of-action and will be a significant addition as a novel treatment approach for HD chorea.” For more information on the Phase IIb study, please visit clinicaltrials.org.
SOM’s Board and leadership has been recently strengthened with the addition of industry veterans to the Board and highly experienced people in the management team to position the company for the next level of growth.